## BPR1M97

Cat. No.:	HY-128865		
CAS No.:	2059904-66-	-2	
Molecular Formula:	C <sub>18</sub> H <sub>18</sub> Cl <sub>2</sub> N <sub>2</sub> C	)	
Molecular Weight:	349.25		
Target:	Opioid Rece	ptor	
Pathway:	GPCR/G Pro	tein; Neu	ronal Signaling
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

®

MedChemExpress

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (715.82 mM; Need ultrasonic)						
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
Preparing 1 n	1 mM	2.8633 mL	14.3164 mL	28.6328 mL			
		5 mM	0.5727 mL	2.8633 mL	5.7266 mL		
		10 mM	0.2863 mL	1.4316 mL	2.8633 mL		
	Please refer to the so	lubility information to select the app	propriate solvent.				
In Vivo	1. Add each solvent of Solubility: ≥ 2.08 r	one by one: 10% DMSO >> 40% PEC ng/mL (5.96 mM); Clear solution	G300 >> 5% Tween-8	0 >> 45% saline			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.96 mM); Clear solution						
	<ol> <li>Add each solvent of Solubility: ≥ 2.08 r</li> </ol>	one by one: 10% DMSO >> 90% cor ng/mL (5.96 mM); Clear solution	n oil				

BIOLOGICAL ACTIV	ТТ
Description	BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with K <sub>i</sub> values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects <sup>[1]</sup> .
IC <sub>50</sub> & Target	Ki: 1.8 nM (MOP), 4.2 nM (NOP) <sup>[1]</sup>
In Vivo	BPR1M97 (1.8 mg/kg; s.c.; once) demonstrates antinociception in a murine model of cancer pain <sup>[1]</sup> .

## Product Data Sheet

NΗ

N

CI

CI

MCE has not independe	ntly confirmed the accuracy of these methods. They are for reference only.
Animal Model:	Male wild-type C57BL/6 mice (25-30 g) <sup>[1]</sup>
Dosage:	1.8 mg/kg
Administration:	Subcutaneous injection (s.c.); once
Result:	Demonstrated antinociception in a murine model of cancer pain.

## REFERENCES

[1]. Chao PK, et al. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, producespotent antinociceptive effects with safer properties than morphine. Neuropharmacology. 2019 Jul 3:107678.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA